Allogene Therapeutics Announces Filing For IPO

September 14, 2018
  • Number of shares and price range yet to be determined
  • Allogene has seven products in pre-clinical development and 1 in Ph I trials

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer, today announced it has filed an S-1 registration statement with the Securities and Exchange Commission (“SEC”) relating to a proposed offering of its common stock. All shares of common stock to be sold in the offering will be offered by Allogene. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Allogene has applied to list its stock for trading on the NASDAQ under the symbol “ALLO.”

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC are acting as the joint book-running managers for the proposed offering.

Allogene currently has seven therapies in pre-clinical development and one in Ph I trials. The drug in Ph I, UCART19, is an investigational allogeneic anti-CD19 CAR T-cell product. It is licensed from Servier.

In one study of UCART19 in Advanced Lymphoid Malignancies (CALM study), the drug achieved molecular remission at Day 28  in five of seven patients. Molecular remission is defined by negative minimal residual disease (MRD). MRD is a measurement of the number of residual leukemic cells that remain after treatment.

In a deal announced in April of 2018, Allogene received rights to 16 pre-clinical CAR T assets from Pfizer that Pfizer had licensed from Cellectis SA. Pfizer announced it would take a 25% stake in Allogene as part of the deal.



CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.